• Nu S-Au Găsit Rezultate

View of A Concise Review on Transdermal Drug Delivery System


Academic year: 2022

Share "View of A Concise Review on Transdermal Drug Delivery System"

Arată mai multe ( pagini)

Text complet


A Concise Review on Transdermal Drug Delivery System

Bharat Lal


, Manoj Gadewar


1Dept. of Pharmaceutics, K.R. Mangalam University, Haryana, India.

2Dept. of Pharmacology, K.R. Mangalam University, Gurgaon, Haryana, India Email:

Author 1: bharat[email protected] Author 2: [email protected] Abstract

The most essential component of pharmaceutical dosage is the Transdermal Drug Dermal Systems (TDDS) which has established themselves as part of the development of new drug delivery systems. The distribution of the medicine through the dermis results in a systemic impact on the administration of Transdermal patches. TDDS is an expensive alternative to traditional wording. The skin is covered with a medicated adhesive patch to provide a specified dose of medication to the skin and bloodstream. This is typically helpful in changing a damaged physique. The advantage of a Transdermal approach is that the patch allows regulated release of the drug, commonly via either a porous membrane covering the medications reservoir or a thin layer of adhesive medicines, via the melting of body thermal content. The patch is also a good way for Transdermal drug administration compared to other drug delivery kinds such as oral. Because of its particular benefit, TDDS is also essential. Some of the possible benefits of transdermal medication delivery include controlled absorption, more consistent plasma levels, increased bioavailability, decreased side effects and easy application, and flexibility to stop drugs simply by cutting away the skin patch. The basic aim of the transdermal medication delivery system is to provide medications with minimum and intra-patient fluctuations into systemic skin circulation. The procedures of preparing several kinds of transdermal patches are described in this review article. Furthermore, numerous strategies for assessing transdermal dose and progressive development of TDDS were also studied.

Keywords: TDDS, Topical, Transdermal film, Reservoir, Epidermis, Drug polymer


TDDS- Transdermal Drug Delivery Systems SCOP- Scopolamine

FDA- Food and Drug Administration EVAC- Ethylene Vinyl Acetate Copolymer

1. Introduction

Since the United States Food and Drug Administration authorized the first scopolamine transdermal patch for motion sickness in 1979, TDDS has received wide interests as a preference option to the administration of oral drugs and hypodermic injections[1]. TDDS offers controlled release into patients of the medicine compared to oral or systemic dosing methods, reducing first-pass metabolism effects, reducing systemic adverse effects, improving dose effectiveness throughout therapy by permitting steady blood drug profiles and improved patient


compliance. However, the good barrier functioning of the skin, especially the stratified organ, in order to avoid the invasion of foreign molecules, restricts significant uses of TDDS. Only a few medicines can passively permeate the skin to achieve efficient blood levels to cure disorders. These medications will usually be very strong, lipophilic and of low molecular weight (<600 Da).

The attention has been revived during the last couple of years in the creation of new mechanisms for the delivery of current medicines molecules. In addition to improving the effectiveness and safety of the treatment, the design of a new delivery mechanism for current drug molecules also significantly enhances patient conformity and total therapeutic benefit[2]. TDDS are characterized as autonomous, discrete dose forms, commonly called as "parches,"[3,4] when patches are attached to the intact skin, and the medication is delivered to systemic circulation via the skin at a regulated rate[5]. TDDS are dosing forms intended to provide a therapeutically effective quantity of medication over the skin of a patient[6].

The principal purpose of the transdermal system is to provide medications with minimum inter and intrapatient variation in systematic skin flow at a set rate[4]. Transdermal delivery is now one of the most promising medication approaches [7]. It lowers the burden of the digestive system and liver that the oral route usually entails. It improves the patient's compliance and reduces damaging side effects of a dose-by-dose medication and makes it easy to utilize transdermally administered medicines that only apply weakly once[8].

This increases the bioavailability, increases plasma levels, increases action time, resulting in reduced dosage frequency, lowers adverse reactions and improved therapy with plasma levels maintained until the end of the dosing interval compared to decreased standard dose plasma levels [9]. In addition to providing regulated medication management for continual distribution, the transdermal distribution permits continued input of short biological semi-lives and minimizes pulsed entrance into systemic circulation, which frequently leads to unwanted side-effects. Various key benefits of transdermal medicine include limited metabolism of the hepatic first pass, improved therapeutic effectiveness and continuous plasma maintenance of the medication. The TDDS is a multidisciplinary activity that encompasses a basic feasibility study ranging from the selection of drug molecules to sufficient drug fluxes in the ex vivo or in vivo version and the production of an anti-drug system that meets all strict medication molecular requirements (physicochemical factors, stability factors) and patients.

The Transdermal SCOP was approved in 1979 by the FDA to reduce travel related nausea and vomiting. It was the first transdermal device. Most transdermal patches will release the active component at zero order rates for several hours or days after the skin is used. this is very good for preventive treatment in chronic diseases [10].

There may be a measured quantity of medicines in the blood, a detectable excretion of the medication in the urine, and clinical reaction of the individual patient to medicine therapies[11] as proof of percutaneous drug absorption.

4.1 Transdermal route and drug delivery prospects 4.1.1 Skin and its function:

The largest organ:


The skin covers around 2 m2, and about a third of the body's blood circulation [6]. The skin is the biggest organ in the man's body. Human skin composed of three layers firstly named as epidermis, which is an outermost layer, secondly beneath epidermis is called as dermis and thirdly as the hypodermis or subcutaneous layer. The epidermis is keratinized in nature and composed of cuboidal shape squamous stratified epithelial cells. It is avascular in nature, providing protection to cells. Skin is composed of four layers refereed as thin skin representing S. Basale, S. Granulosum, S. spinosum and S. corneum and thick skin referred as S. Lucidum. The second layer referred to as the dermis, vascularised and provides support and flexibility to the tissues and composed of a dense network of connective tissues having blood vessels, sweat glands and hair follicles. The innermost layer called as hypodermic composed loose connective tissues having Adipocytes having lipid storage effects, serves as energy reserves, regulate temperature and provide insulation in the body. This layer is highly vascularised in nature.Skin was a barrier to the permeability of transdermal absorption of many chemical and biological substances. It is one of a few millimetres thick and readiest organ in the body (2,97 0,28 mm), Skin plays a number of functions such as itacts as a barrier against physical, microbiological and chemical assault.Skin isolates from the outside the underlying blood circulation system and helps to control blood pressure. It also provides protection against the UV rays. Simply put, skin is an important element in influencing the different features of medication administration, such as drug penetration and drug absorption via the dermis.

The skin's diffusive strength depends considerably on its structure and architecture [13].

4.1.2 Anatomy of Skin:

The human skin is composed of three primary layers (fig 1):

 The epidermis, which provides waterproofing and serves as a barrier to infection.

 The dermis, which serves as a location for the appendages of skin.

 The hypodermis subcutaneous adipose layer[14]

Layers of Epidermis:

This epidermis consists mostly of two parts: a living or viable cell (viable epidermis) in which the malignan cell is a permanent epidermis, covering the whole surface of your body. The epidermis is split into multiple layers in which cells originate in the innermost layers by mitosis. They shift the form and content of shifting strata as they differentiate and fill with keratin. Finally they reach the top layer known as corneal stratum. The process, which takes occur within weeks, is termed keratinisation. The epidermis' external layer has between 25 and 30 layers of fallen cells.


Epidermis is divided into the following 5 sub layers or strata:

 Stratum corneum

 Stratum lucidum

 Stratum granulosum

 Stratum spinosum


 Stratum germinativum

Figure 1: Different layers of skin

Skin function: Mechanism of Drug Absorption

Stratum corneum also known as a horny layer of the outermost skin. The obstruction characteristic of the horny layer is strongly based on its components: 75% to 80% of the dry protein, 5% to 15% lipid and 5% to 10%

ondansetron. The corneocypts are submerged in a lipid matrix which is critical for determining the penetration of the skin [12].Viableepidermisis located below the stratum corneum. Cell mitosis in the basal layer continually renews the epidermis [15].Dermis is the skin layer underneath the 3-5 mm thick layer of the epidermis. The dermal blood supply has a key role to play in the body temperature control. Capillaries serve a sink for most skin barrier molecules in this layer and maintains dermal penetration level. For the delivery of transdermal medicinal products this is frequently seen as simply gelled water and hence constitutes a minimum obstacle when most polar substances are delivered[14].The dermis and epidermis are supported by hypoderma or subcutaneous fat tissue. The layer serves to control the temperature, supports and protects mechanically. It brings main blood veins and nerves to the skin and may include organs with sensory pressure. To distribute transdermal drugs, all three layers must be penetrated and systemic circulation reached [15].

Permeation of drug molecule through skin

The first law of the Fick Diffusion Drug molecule diffuses from an area with a high concentration to a low concentration until balance is reached. It expresses this. The process of molecular diffusion is driven by gradient from high to low concentration.


Figure 2: Mechanism of drug adsorption through skin

The dosage form releases the drug and a series of steps governs its path towards the dermis for treatment of skin disorders. Therapeutic Phytoconstituent partition and diffuses into the dermis after penetration through epidermal layer. The phytoconstituent reaches systemic circulation and used in the treatment of skin disorders.

A graphical representation of its mechanism (Barry et al., 1991) is summarized in Figure 2.

Percutaneous absorption:

In the 16th century B.C. the notion of percutaneous absorption arose (Finnin and Morgan, 1999). Evidence showed that several chemicals, particularly gases and volatile compounds had free skin penetration throughout the time leading up to 1878. In the years 1877 and 1900, Fleisher was in the position to establish that human and some animal skin was totally impermeable to all sorts of chemicals via tests and rigorous analyses. Percutaneous absorption is the word used most often for the transport of medications via the skin, though numerous other literature words such as: sorption, persorption, permeation and penetration may be found. Simply put, the definition of percutaneous absorption is that chemicals penetrate different levels of skin and that permeate the epidermis into systemic circulation[12].


Figure 3: Pathways of permeation through skin Percutaneous absorption done by 2-ways[12]- (see fig 4)

(A) Transepidermal Absorption

Molecules transverse the intact horny layer in transepidermal transfer. The transcell (or intracellular) and the intercellular pathways exist, two possible micro routes.Polar and non-polar chemicals diffuse by various ways


spanning transcellular and intercellular pathways. Polar molecules spread mostly by the hydrated corneal stratum across the polar channel, while nonpolar molecules decline and spread through the non-aquaeous lipid matrix of the stratal cornea. The main route of a penetrator is thus mostly characterised by the partition coefficient (log K). Lipophiliac (octanol/water log K>2) enters the eye layer through a cross-phase in hydrophilic intracellular division medication. Most chemicals move through the layer cornea in both directions [6].

(B) Transfollicular Absorption

This pathway involves the transportation of hair follicles and sebaceous glands through the sweat glands. Whilst these pathways are highly permeable, their area of around 0.1 percent of total skin, is thought to be of modest consequence. This path seems to be more essential for ions and big polar compounds that do not penetrate the stratum corneum[6]

Only secondary permeation routes may provide skin appendages. The follicular path is significant pathway for percutaneous absorption as the opening of the follicular pores in which the hairpin leaves the skin is quite big.

Steps involved in transdermal permeation of drug:- i) Sorption by stratum corneum

ii) Penetration of drug through viable epidermis

iii) Uptake of drug by capillary network in the dermal papillary layer.

In the Transdermal mode of drug administration, the drug needs to be properly absorbed and rates used for achieving and maintaining uniform, systemic, therapeutic levels throughout its usage. When the medication


molecule crosses the barrier of the stratum, it quickly and easily goes into deeper dermis and systemic uptake [10, 16].

Figure 4: Percutaneous absorption Factors affecting transdermal permeation

i) Physicochemical property of Drug molecule

 Partition co-efficient,

 pH Condition,

 Drug Concentration

ii) Physicochemical property of Drug Delivery System

 Release characteristics,

 Use of permeation enhancer,

 Composition of Drug Delivery System iii) Pathophysiological condition of Skin

 Reservoir effect of Horney Layer

 Hydration of skin

 Lipid Film

 Skin Temperature

2. Materials and Methods

This is a review article on "Delivery systems for transdermal drugs." The research employed secondary data to evaluate the research's objective. The secondary data sources often comprise different data, books, periodicals, journals and business journals published or unpublished. Relevant research from various secondary data sources,


such journals, books etc. have been chosen. A systematic review is described as an "evidence review on a clearly defined subject that employs consistent and explicit techniques of identifying, selecting and critically assessing the relevant original research, and extracting and analyzing information from studies included in the review." Reproducible and transparent approaches are employed.

3. Results and Discussion

TRM is a non-invasive distribution of medicinal products to the circulatory system from the skin's surface — the most big and accessible organ in the human body.

The first transdermal patch was allowed to treat nausea and vomiting associated with movement in 1981. The FDA has authorised $6 trillion – over 25 authorised FDA patches on the US market and more than 40 in clinical trials[18] are accessible. The patches of fentanyl, nitroglycerine, estradiol, sthinylestradiol, norethindron-acetate, testosterone, clonidine, nicotine, iodcaine, prilocaine and scopolamine are used as the basis of 11 drug compounds.

Two newly authorised transdermal patches (a pill containing ethinylestradiol and nasal elgestrom) and an overactive oxybutynin-containing bladder patch to treat.

TDDS provides several benefits over traditional and oral injections.

Advantages of TDDS: [18, 19, 20, 21]

 Avoiding first-pass effect

 Stable blood level and blood regulated

 Comparable intravenous infusion features.

 Long term duration

 TDDSprovides no interference with gastric and intestinal fluids.

 Administer drugs with very short half-life, narrow therapeutic window and poor oral absorption.

 Improved patient compliance.

 Self-administration is possibleand it also prevent parenteral treatment discomforts.

 Systems are non-invasive.

 A simple dosage scheme may help patients stick to pharmacological treatment, particularly with patches which need just once a week.

 The patch also allows continual administration of drug-related medications instead of the peaks and valleys.

 Provide short-term, restricted therapeutic window use of the medicine with low adverse reactions.

 transdermal patches are preferable for supplying drugs which are not easily absorbed from the gut or destroyed by the liver, which are broken down by the stomach help.

 It is a replacement fororal route, the cost-effective transdermal patches are quite beneficial.


Limitations of TDDS: [19,21]

 The delivery method of ionic medicines cannot be transdermic.

 The medicine must have desired physicochemical characteristics for stratum corneal permeation.

 Unable to obtain high blood concentrations of medications;

 Unable to develop for big molecular medicines.

 Unable to pulsatily distribute medicines.

 Skin irritation or contact dermatitis due to drug or excipients.

 May produce a response to allergy.

 Enduring permeate for the transverse stratum corneal and the underlying aqueous stratum, a value P (octanol/ water) between 1 and 3 is needed.

 Powerful medications are the only choices that are suited for transdermal patches due to the inherent restrictions imposed by the impermeability of the skin.

 Barrier function of the skin on the same person, individual and age varies from one location to another

 It's tough to adhere long-term.

Kinetics of transdermal permeation: [18]

Kinetics of skin penetration is crucial for the efficient development of transdermal devices. Penetration of transdermal drugs is the,

 ―Sorption by stratum corneum”

 ―Penetration of drug through viable epidermis‖

 ―Uptake of the drug in the dermal papillary layer‖

Factors affecting transdermal permeation

Biological component include circumstances of the skin, age, blood supply, regional skin location, skin metabolism, variations in species; Physicochemical parameters include skin moisture, temperature and pH, coefficient of diffusion, concentration of drugs, coefficient of partition, molecular form and size;Environmental factors such as sunlight, cold season, air pollution, heat are some of the factors that affect transdermal permeation[16, 22, 24].

Effect of Heat on Transdermal patch: [24]

High absorbance of transdermal drugs has been caused by heat. The application location should not be exposed to outside heat sources, such as water bags and hot water bottles. Patients should be advised to. The transdermal


supply of medicines may potentially enhance even high temperatures in the body. The patch should be deleted instantly in this instance. Transdermal medication patches are stored and kept cold and secure until they are ready to be used in their original package.


Transdermal patches are formulated in such a way that it has all the features such as relatively invariant composition in application, reasonable system size, application site defined, highly replicable technical application, zero order delivery and, efficient supply [18, 22,23].

Basic Components of TDDS:

1) Polymer matrix / Drug reservoir.

2) Drug.

3) Permeation enhancers.

4) Pressure sensitive adhesive (PSA).

5) Backing laminates.

6) Release liner.

7) Other excipients like plasticizers and solvent.

Polymer matrix / Drug reservoir: The core of TDDS is polymers that govern the release of medicines from the equipment. Polymer matrix may be formed by spreading the medicament into the synthetic base of fluid or solid form. TDDS polymers should be stable and compatible with the components of drugs and other systems and should efficiently release drugs in safe settings [27].

Selection of drugs: TDDS medication selection depends on the physicochemical characteristics of the medicine. The approach of transdermal distribution is more suited to having medicine [30].

Permeation enhancers:These compounds help to raise the permeability of a stratum corneum via interacting with structural components of a stratum corneum, e.g. proteins or lipids, in higher medicinal therapeutic content. Stratum corneum proteins and lipids are modified to increase permeability through chemical changes in barrier functions. Examples include: Dimethyl sulfoside; Propylene glycol; 2- pyrrolidone; Isopropyl myristete; Laurocapram (azone); Sodium laurithic sulphate [28].

Pressure sensitive adhesives:The pressure-sensitive adhesive (PSA) firmly attaches to the skin the transdermal medicine supplier. With just applied finger pressure, it should be connected strongly and continuously and should have a strong hold power. It should also be removed without leaving a residue from the smooth surface. Skin compatibility, little irritation or sensitivity must occur, and must be removed without physical stress or residues. In addition, medicines and excipients must be able to dissolve in levels suitable for the requisite pharmacological activity without losing adherence and skin tolerance. Polyacrylates, polyisobutylene and polysiloxane are used in commercially available transdermal systems [32].


Backing laminate: Supports must be flexible yet the tensile strength is good. The often used materials include transparent, coloured, or metallized polyolefin, polyester and elastomers. Elastomeric materials like polyethylene with a low density more easily adapt to skin movement and give greater adherence than materials that are less compatible such as polyester. In order to encourage higher skin hydration and therefore higher skin permeability, support materials should also have a small rate of transmission from water vapour. The backpack material must be heat-sectable for systems storing drugs in a liquid or gel to enable fluid-tight packaging of the medical stock via a technique known as form-fill-section.

A low module or high level of flexibility will be the most comfortable support, with excellent oxygen transmission and a high rate of humidity vapour transfer[27].

Some supports include vinyl, polyester films, polyester-polypropylene foil, polypropylene resin, poly- ethylene resin, polyurethylene, film Co Tran9722, acetate, laminate aluminum-plastic Examples of some background materials.

Release Liners: The patch is coated with a protective liner during storage, which is promptly removed and unloaded before to placement to the skin. This consequently applies rather than part of the dosage form for the delivery of the medicine as a component of the principal packing material [27,9].

The liner should meet, however, particular demands for chemical inertness and permeation of the medication, penetration enforcer and water, since it comes in direct touch with the supply system. The released linen usually consists of a non-occlusive or occlusive layer (for example, a paper texture) and a release coating composite layer consisting of silique or teflon. a layer of the release layer may be composite.

Other excipients: Various solvents are used to manufacture drug reservoir 18, 32 such as chloroform, methanol, acetone, isopropanols and dichloromethane. In addition the transdermal patch is plasticized with plasticizers such as dibutylpthalate, trietylciitrate, polyethylene glycol and propylene glycol [28,37].

Preparation of transdermal drug delivery system: Methods[37]

Asymmetric TPX membrane method:

The rear membrane may be formed of a patch of the prototype with 1cm diameter concave film (type 1009, 3m).

The medication sample should be sent to the concave membrane, covered with asymmetric TPX {poly(4- methyl-1-pentene)} and screened with adhesive [7].

Asymmetric TPX membrane preparation

The dry/wet reversing systems are made. The TPX is dissolved in the solvent (cyclohexane) and non-solvent combinations at 60°C for generating a polymer solution. The polymer solution is held at 40°C and cast onto a glass panel with a preset thickness using a gardening knife. The glass plate has to be immediately dipped into a coager [the temperature maintained at 25°C] once the casting film has been evaporated for 30 seconds at 50°C.


The membrane may be removed in a circulating oven at 50°C for 12 hours after 10 minutes of soaking and air dry) [4].

Mercury substrate method:

In this process, medicine is dissolved along with plasticizer in a polymer solution. The above-mentioned solution must be swirled in an even dispersion for 10-15 minutes and filled into a flat surface. The solution is then reversed to the solvent evaporation control [7].

Circular teflon mould method:

Polymer solutions are employed in different ratios in organic solvents. A half the organic solvent is the estimated quantity of the medication. The enhancers are dissolved and added to the other part of the organic solvent at varying concentrations. As a plasticizer in a solution for the drug polymer, di-N-butylphthalate is utilised. In a circular teflon mould, all material should be rotated for 12 hours. The moulds are set on a flat pad and include a reverse funnel to modify damping solvents in a 1/2 m/second air speed laminar flow hood. The solvent might evaporate within 24 hours. Dry film in a silica gel-containing desiccator should be kept for another 24 hours at 25±0.5°C to avoid the effects of ageing. Such films must be assessed within one week [38].

By using “IPM membranes” method:

Dispersed in a combination of 940polymer carbomer-containing water and propylene glycol, this approach is mixed with magnetic agitator for 12 hours. By adding triethanolamine, the dispersion must be neutralized and viscous. PH buffer 7.4 may be utilized for solution gel if the aqueous solution is extremely low in the pharmaceutical solubility. The generated gel in the IPM membrane is added [4].Aluminium backed adhesive film method:

The transdermal mode of supply of drugs may cause unstable matrices when the dosage of load exceeds 10 mg.

Aluminum supported adhesive film technique is a suited for preparing the same, chloroform is a solvent option, since chloroform solubility is the majority of medications and adhesives. This drug was dissolved in chloroform and dissolved into the adhesive solution. The metal form is unusual, and the ends are surrounded with cork blocks [7].

By using “EVAC membranes” method:

The membranes used to manufacture a target trading system may include 1 percent carbopoly reserve gel, polyethelen (PE), vinyle acetate ethylene copolymer (EVA). If the drug is not water-soluble propylene glycol, the propylene glycol is used to make the gel and to neutralise the glycol by employing a 5% sodium-hydroxide solution. The medicine is deposited on a backing layer covering the given region (in gel form). A membrane that controls the gel is installed and the borders are heat-screened to achieve a leak resistant device [4].

By using free film method:

The free film is cast on a cellulose acetate mercury surface. Chloroform produces a 2 percent w/w polymer solution. Plastizers are incorporated at a concentration of 40% W/P of polymer weight. A ring of glass was filled with five ml of polymer solution on the mercury surface on a glass petri dish. The velocity of solvent


evaporation is controlled by placing an inverted drum over the petridish. After complete solvent evaporation, a surveillance of the mercury surface shows the production of the film. The dried film is separated and kept in desiccators between the wax paper sheets. The amount of the polymer solution may be changed to produce free films of varied thicknesses[7, 29].

Preparation of TDDS by using proliposomes:

Use of film deposition technology to manufacture proliposomes using carrier method - An optimal ratio of 1:2 may be used with the previous reference medicines and lecithin. The proliposomes are prepared using a 100 ml circular base with 5 mg of mannitol powder, 60-70 °C, spun with 80-90 rpm, with mannitol dried with vacuum for 30 minutes. The water bath is changed to 20-30°C after drying. After drying procedure. The medicine and lecithin are dissolved into an appropriate organic solvent combination. After the second aliquots (0.5 ml) of the solution are fully drained, a fluid of 0,5 ml organic solution is put in the bottom circular flat at 37°C containing mannitol. After the final load, the flask is linked by a lyophilizer to the proliposome and medicinal mannitol powders are deposited in overnight drying systems. The selected powder is put in a glass container and stored until freezing cold characterization [7].

Evaluation Methods[20,36,40]:

The assessment techniques may be categorised as follows. Transdermal dosage form:

(i) ―Physicochemical evaluation‖

(ii) “In vitro evaluation‖

(iii) “In vivo evaluation‖

i) Physicochemical evaluation:

Transdermal patches may be physically assessed by these factors:


Digital micrometre is used at various points of patch to determine the drug's thickness and standard variation to assure the thickness of the created patch. The average thickness and defect are.


For 4 hours before to testing the prepared patches should be dried at 60°C. A given patch area is to be chopped and weighed in the digital balance in various portions of the patch. The weight of the individual weights must be measured in average and standard deviations [28,36].

Drug content determination:

A well-weighted segment of the film (about 100 mg) is dissolved in 100 ml of suitable solvent with the solution soluble and agitated for 24 hours continuously in shaken incubators. Then the whole solution is sonicated.


Species dilution following sonisation and subsequent filtration is assessed spectrophotometrically by the solution [39].

Content uniformity test:

The contents of every patch are selected by selecting 10 patches when the content of 9 out of 10 patches ranges from 85% to 115%, while the value of the one patch ranges from 70% to 125%, then the uniformity of the content test is achieved by transdermal patches. However, if three patches have 75% to 125% content, another 20 patches for drug content will be tested. The transdermal patches are tested whether the range of the 20 patcher is 85% to 115% [31].

Moisture content:

The manufactured patches should be individually weighed and maintained at room temperature in a dryer containing fused calcium chloride. After 24 hours, the films should be weighed and the proportion of moisture using the following formula determined:

Moisture content = (Final weight– Initial weight)/final weight X 100

Moisture Uptake:

The preparations must be individually weighed and maintained in a desiccator with potassium chloride saturated solution to keep RH at 84%. After 24 hours the film should be weighed and the moisture consumption using the following formula should be determined;[35].

% moisture uptake = (Final weight– Initial weight)/Initial weight X 100


Each film has to be cut into three longitudinal strips at various parts, such one from the centre, another from the left and one from the right. The length of each strip was measured and the difference in length was assessed by a percentage restriction since the flatness was not uniform.

% constriction = I1 – I2 X 100 I2 = Final length of each strip I1 = Initial length of each strip [31]

Folding Endurance:

A certain strip area is cut and repeatedly folded till it has broken. At the same spot. The quantity and durability of the film could be folded without breaking [33,40].

Tensile Strength:

Polymeric films are individually sandwiched with corked, linear iron plates in order to evaluate tensile strength.

One end of the films is fastened by an iron screen and a freely mobile thread is linked to the other. The weights


are progressively added to the pot tied to the thread hanging end. The elongation of the film is measured using a pointer on the thread. The weight of the film is just enough to shatter [28].

Tack properties:

It is the polymer's capacity to attach with low contact pressure to a substrate. The molecular weight, composition and application of tackling resins in polymers depends on the molecular tackle [32].

Thumb tack test:

The strength to get thumb out of the glue is a tack measurement [33].

Rolling ball test:

The test includes measuring the distance of an upward face of a stainless steel ball. The tighter the glue, the more the ball moves [32].

Quick stick (Peel tack) test:

The tapestry is removed at a pace of 12 inches/min from the substrate at 90oC. The needed peeling strength is determined and reported as a tack-value indicated in onces or grammes per inch of width [19].

Probe tack test:

In this test, a speed of 12 inches per minute is drawn out from the substratum at 90oC. The force needed to break the connection between adhesive and substratum is measured and recorded as a tail value, which is shown in ounces or grammes per inch of width [28].

ii) In vitro release studies:

In vitro drug release studies

The disc paddle (USP appliance V) technique may be used to evaluate the release of the medicine from the prepared patches. Known thickness drying sheets must be cut into a certain form, weighed and fastened with an adhesive over a glass plate. A 500 mL dissolving media or a phosphate buffer (pH 7.4), then inserted the glass plate and balanced the device to 32± 0.5°C. At a distance of 2.5 cm from the glass plate, the paddle was then set and operated at 50 rpm speed. Samples (5- ml aliquot) may be removed using the HPLC or UV spectrophotometer at suitable times of up to 24 hours. The test should be done three times and the average value should be computed. [34].

In vitro skin permeation studies

The diffusion cell may be used to perform an in vitro permeation research. Male Wistar rats weighing 200 to 250 grammes. Full thickness Abdominal skin. Hair from the abdominal area must be carefully removed with an electrical clipper; the skin's dermal side has been thoroughly cleaned in distilled water to remove all adherents tissues or vessels, balanced for an hour with the medium dissolution or phosphate buffer pH 7.4 before the experiment starts. A thermostat-controlled heater kept the temperature of the cell at 32 ± 0.5 °C.


The individual piece of rat skin should be positioned between the diffusion cell compartments with the epidermis facing up into the donor compartment. The sample volume of a certain volume should be taken regularly from the receiver cell and the fresh medium should be replenished by the same amount. Samples must be filtered using a spectrophotometric or HPLC media and may be evaluated. Flux may be estimated simply by dividing the flux by the first drug load as the slope of the curve between the stable values of the quantity of penetrated (mg cm2) vs. time in hours (mg cm2)[34].

iii) In vivo Studies:

In vivo assessments show the genuine results of the medicine. During in-vitro investigations, factors that cannot be taken into consideration may be studied in full. TDDS may be evaluated in vivo using: animal models and volunteers. [28].

Animal models:

There is a need for considerable time and money for human investigations, so that animal experiments on a limited scale are recommended. Mouse, hairless rat, hairless dog, hairless rhesus monkey, rabbit, guinea pig are the commonest animal species utilized in assessing transdermal pharmaceutical systems. Different investigations have led to the conclusion that in both in vitro and in vivo trials, hairless animals are favored over hairy ones. One of the most accurate in vivo measurement models of human transdermal administration Rhesus monkey [28].

Human model

After application of the patch by human volunteers at the final stage of the development of a transdermal device, pharmacokinetic and pharmacodynamic data are obtained. Clinical investigations have investigated the efficacy, risk involved, side-effects and patient compliance. Phase II clinical trials for short-term safety and effectiveness in patients are typically undertaken in the determination of safety in volunteers and Phase II clinical trials. The safety and effectiveness of a variety of people in the patient population is suggested by Phase III research, and Phase 4 studies are carried out after commercialisation to discover patches of adverse reactions. Although human studies need significant resources, they are the greatest way to measure the drug's performance [28,40].

Transdermal Patches:Applications

 Nicotine patch, which delivers nicotine at regulated levels for the sake of cessing tobacco smoking is the biggest selling transdermal patch in the United States.

 Two opioid drugs used to relieve severe pain 24/7 are usually supplied patch-form: fentanyl (marketed as Duragesic) and buprenorphine (marketed as BuTrans).

 CE patches of oestrogen are occasionally recommended for treating both menopause and postmenopause osteoporosis. The contraceptive patch includes other transdermal patches for hormone administration (marketed as Ortho Evra or Evra).


 T henitroglycerine patches may be administered in place of sublingual tablets for the treatment of angina.

 The first antidepressant transdermal administration drug has been transdermal version of the MAOI selegiline.

 The transdermal patch variant of the anti-hypertension medicine Clonidine [21].

TDDS: scope

The scope of TDDS in future includes[23,25]:

 A tennis elbow therapy Dexamethasone iontoporetic administration.

 A Post-menopausal women's Estrogen and Testosterone Patch.

 To a patch of insulin.

 Check out Varenicline smoken cessation patch and the quick metabolizers high-dose nicotine patch.

 Selegiline Patch for geriatric depression and addiction to cocaine.

 To mention only a few, transdermal transdermal stroke glyceryl trinitrate.

 Current chronic cancer pain patch Sufentanil.

 os A migraine therapy iontophoretic sumatriptan patch.

 Clonidine transdermal in trauma patients for treatment of delerium.

4. Conclusion

Rational drug treatment systems (safe, effective, and cost-effective) drug delivery instruments are utilized as transdermal systems. Due to the great benefits of the TDDS, many additional studies are now underway to integrate new medicines into the system. A transdermal spot comprises various essential components, such as drug reservoirs, liners, adhesives, enhancers of permeability, laminates, plasticisers and solvents that play a critical part in the release of the medicine via the skin. Various techniques of preparing these patches are utilized with TDDS basic components. They are assessed for physical-chemical, in-vitro, skin irritation and stability investigations after production of transdermal patches. However, all transdermal patches developed and analyzed have to be approved by FDA before they are sold. Increased control and further extension of accessible medications is probably the priority for future development of TDDS. Transdermal dose forms may provide physicians extra treatment alternatives to maximize treatment for their patients.

5. Conflict of interest

There is no conflict of interest.


6. Bibliography

[1] Prausnitz, Mark R., and Robert Langer. (2008). "Transdermal drug delivery." Nature biotechnology, 1261-1268.https://www.nature.com/articles/nbt.1504

[2] Jalwal, Pawan, et al. (2010). "A review on transdermal patches." The Pharma Research, 3, 139-149.https://www.ajol.info/index.php/tjpr/article/view/44527

[3] Subedi, RobhashKusam, et al. (2010). "Recent advances in transdermal drug delivery." Archives of Pharmacal Research 33.3, 339-351


[4] Kumar, J. Ashok, et al. (2010). "Transdermal drug delivery system: an overview." Int J Pharm Sci Rev Res 3.2, 49-54.


[5] Divya, A., et al, (2012). "A review on current scenario of transdermal drug delivery system." Int. J Res. Pharm Sci 3.4 , 494-502.


[6] Jain NK, (2001)Controlled and novel drug delivery. 1


, CBS Publisher and Distributors, New Delhi.,100-129.


[7] Rani, Shalu, et al. (2011): "Transdermal patches a successful tool in transdermal drug delivery system: an overview." Der Pharmacia Sinica 2.5, 17-29.


[8] Aggarwal, G., and S. Dhawan. (2009). "Development, fabrication and evaluation of transdermal drugdelivery system-a reiew Pharm.

https://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra05803a/unauth#!divAbstract [9] Patel D, Chaudhary SA, Parmar B, Bhura N. (2012), Transdermal drug delivery

system: a review. The Pharm Innovation. 1.4, 66-75.


[10] Mehta, Ratan. (2004): "Topical and transdermal drug delivery: What a pharmacist needs to know." Inet Continuing education, InetCE. com 1-10.



[11] Loyd V, Allen Jr, Nicholas G, Popovich, Howard C, Ansel. (2005)Pharmaceutical dosage forms and drug delivery systems, 8


, Wolter Kluwer Publishers, New Delhi, 298-299.


[12]Jain NK. Pharmaceutical product development, (2002)1


CBS Publisher and Distributors. New Delhi, :221-228.

https://www.abebooks.com/Pharmaceutical-Product-Development-K-Jain- CBS/843262756/bd

[13]Robinson, Joseph R., and Vincent HL Lee. (1987).Controlled drug delivery:fundamentals and applications/edited by Joseph R. Robinson, Vincent HL Lee. New York: Dekker.

https://www.worldcat.org/title/controlled-drug-delivery-fundamentals-and- applications/oclc/1028561818

[14]Waugh, A., and A. Grant. (2001)."Anatomy and Physiology in Health and Illness.

Churchill. Livingstone." http://old.mu.ac.in/wp-content/uploads/2016/06/4.18-C- Revised-SN-Syllabus.pdf

[15]Sharma, Nikhil, et al. (2011) "A review: transdermal drug delivery system: a tool for novel drug delivery system." Int J drug dev Res 3.3: 70-84.

https://www.researchgate.net/publication/281653618_Formulation_and_evaluation_of _etodolac_lecithin_organogel_transdermal_delivery_systems

[16]Ramteke, K. H., S. N. Dhole, and S. V. Patil. (2012)"Transdermal drug delivery system: a review." Journal of Advanced Scientific Research 3.1: 22-35.


[17] Research and Markets. (2021). United States Transdermal Patch Market Insights

2021-2026: Market Will Surpass $6 Billion - More Than 25 FDA Approved Patches

Are Available In The US Market And More Than 40 Are In Clinical Trials. Retrieved

from: https://www.prnewswire.com/news-releases/united-states-transdermal-patch-



approved-patches-are-available-in-the-us-market-and-more-than-40-are-in-clinical- trials-

[18]Yadav V. (2012).Transdermal drug delivery system: review. Int. J Pharm Sci. Res.2.3, 376-382.

https://ijpsr.com/bft-article/transdermal-drug-delivery-system-review/?view=fulltext [19]Dhiman, Sonia, Thakur Gurjeet Singh, and Ashish Kumar Rehni. (2011).

"Transdermal patches: a recent approach to new drug delivery system." Int J PharmSci 3.5,26-34.


[20]Keleb, Eseldin, et al. (2010)."Transdermal drug delivery system-design and evaluation." International Journal of Advances in Pharmaceutical Sciences 1.3.


[21]Premjeet, Sandhu, et al. (2011) "Transdermal drug delivery system (patches), applications in present scenario." Int J Res Pharm Chem 1.4: 1139-1151.


[22]Singh, Meera C., Ajinkya S. Naik, and S. D. Sawant. (2010) "Transdermal drug delivery systems with major emphasis on transdermal patches: A review." J Pharm Res 3.10:2537-43.

https://jprsolutions.info/files/final-file 57b3055e0e58e0.34237478.pdf

[23]Saroha, Kamal, Bhavna Yadav, and Benika Sharma. (2011)."Transdermal patch: a discrete dosage form." Int J Curr Pharm Res 3.3,98-108.

https://d1wqtxts1xzle7.cloudfront.net/30398851/368.pdf?1357331487=&response- contentdisposition=inline%3B+filename%3DTransdermal_patch_A_discrete_dosage_


[24]Tom WC. Effects of heat on transdermal drug patches. 1




[25]Bhowmik, Debjit, KP Sampath Kumar, and Lokesh Deb, (2016). "Buccal drug

delivery system-a novel drug delivery system." Research Journal of Science and

Technology 8.2:90. https://www.researchgate.net/profile/Debjit-Bhowmik





[26]Keleb, Eseldin, et al, (2010). "Transdermal drug delivery system-design and evaluation." International Journal of Advances in Pharmaceutical Sciences 1.3,201- 211.https://www.proquest.com/info/openurldocerror

[27]Yadav B, Sharma B, Saroha K(2011). ―Transdermal patches: a discrete dosage form‖.

Int. J Current Pharm Res. 3.3, 98-108.

https://www.academia.edu/2361464/Transdermal_patch_A_discrete_dosage_form [28] Gupta IK, Chokshi MM, (2011). ―Transdermal drug delivery system: an overview.‖

Asian J Pharm Sci. Clinical Res. 1.1,25-43.

[29]Jatav VS, Saggu JS, Jat RK, Sharma AK, Singh RP, (2011). ―Recent advances in development of transdermal patches.‖ Pharmacophore Int. Res. J. 2.6,287-297.



[30]Joshi, Kasturi, and Guna Selvaduray, (2008). "Transdermal drug delivery systems and their. use of polymers." MatE 175–Biomaterials 1, 1-2.


[31] Patel, D. S., et al. (2012)"Transdermal patches: a complete review on transdermal drug delivery system." International journal of pharmaceutical research scholar 1,62- 78.

https://www.ijprs.com/article/transdermal-patches-a-complete-review-on-transdermal- drug-delivery-system/

[32]Lende LK, Grampurohit ND, Gaikwad DD, Gadhave MV, Jadhav SL. (2011).

―Transdermal patches: a review.‖ Int. J Pharm Res. Dev. 4.3, 96-103.

https://ijpsr.com/bft-article/transdermal-drug-delivery-system-a-review/?view=fulltext [33]Sakalle P, Dwivedi S, Dwivedi. (2010). A. Design, evaluation, ―parameters and

marketed products of transdermal patches: a review.‖ J Pharm Res. 3.2,235-240.


[34]Thejaswi, C., et al. (2011)."A review on design and characterization of proniosomes as a drug carrier." IJAPN 1,16-19.



[35]Sachan B, Bajpai M.(2013).‖ Transdermal drug delivery system: A review.‖ Int. J Res. Dev. Pharm and life Sci. 3.1,748-765.


[36]Bathe, Ritesh, and R. Kapoor. (2015) "Transdermal drug delivery system:

formulation, development and evaluation-An overview." drug delivery 6: 7.



[37]Patel D, Chaudhary A S, Parmar B. (2012),Transdermal drug delivery system: A review. The Pharm Innovation,1(4):66-75.

[38]Shingade GM, Aamer Q, SabalePM, Grampurohit ND, Gadhave MV, Jadhav SL, Gaikwad D. (2012) ―Review on: Recent Trends on Transdermal Drug Delivery System‖. J Drug Delivery Therapeutics 2(1),66-75.


[39]Sharma, Ajay, Seema Saini, and A. C. Rana. (2013), "Transdermal drug delivery system: a review." International Journal of research in pharmaceutical and biomedical sciences 4.1 286-292


[40]Mali, Audumbar Digambar. (2015)"An updated review on transdermal drug delivery systems." skin 8.9.

https://d1wqtxts1xzle7.cloudfront.net/38847575/Mali_IJASR_TDS_Review_Publishe d_PDF.pdf?1442902000=&response-content

[41]Gaikwad AK.. (2013).―Transdermal drug delivery system: Formulation aspects and evaluation.‖ Comprehensive J Pharm Sci. 1.11-10.




In this transdermal system, the drug reservoir is being encapsulated in a narrow space in between backing laminate and rate-controlling membrane. The reservoir is

This is especially true for medications that are difficult to absorb via the nasal membrane 33 .Non-mucoadhesive solution and powder formulations have been proven

Drug along with polymer are mixed in a simple solvent and upon solvent vaporization, in matrix systems, a solid solution or a tight medium (drug adsorbed in

Thus there is need to foster a reasonable medication framework that disseminated the dynamic drug particle just to the site of activity, drug conveyance is a strategy

● They can improve drug molecules' therapeutic performance by protecting them from the biological environment, resulting in better availability and controlled

Shanshan Hu et al [4] proposed to use a novel convolution neural network that comes under deep learning is used to predict drug-target interactions based on drug structure and

Transferosomes are ultra-deformable vesicles for transdermal applications consisting of a lipid bilayer with phospholipids, edge activator.The ratios of individual

Calcium carbonate in its micro and nano sizes modified with PEG has been shown to be efficient drug delivery agent (37,40,53), however, there is no information of

The Holoxan drug release profile of synthesized biocompatible nanotubes showed that the nanotubes served as drug carrying vehicles for hard tissue repair in bone

Although 1:2 ratio has relatively high drug content than 1:3 and 1:4 ratios, this formulation was not selected for further studies due to low drug entrapment (58%) which implies a

In this study, tPA-encapsulated PLGA and PLGA/CS were fabricated and drug delivery has been characterized in terms of particle size, thermal analysis, encapsulation efficiency, drug

In vitro mucosa permeation studies were performed to compare the permeation of curcuminoids from 4 different nanoemulsion formulations (F1 to F4) and aqueous solution of

Films with different drug load and polymer concentration were prepared and studied for their thickness, moisture absorption, and In vitro drug permeation. g) Effect of

All over the world, scientists are focusing to develop such a potent drug or vaccine using nanotechnology which can be an effective tool against the deadly disease leishmaniasis

According to our previous investigations it seems that tolerance, whether regarded as a political practice or a philosophical or moral principle, is a strategy (or tactics) of one

The number of vacancies for the doctoral field of Medicine, Dental Medicine and Pharmacy for the academic year 2022/2023, financed from the state budget, are distributed to

Drug utilization study in post-operative patients in surgical ward of a tertiary care hospital attached with medical college. How to investigate drug use in health

drug interactions and inadequate dose [30], need for additional drug therapy as reported by Ali et al[26], ineffective provided drug and need of additional drug as reported by

1) Survey the proportion of medical records experiencing drug interactions. 2) Analyze the relationship between the amount of medicine used in the medical record and the

With strong evidence of protease involvement in diseases, proteases serve an important and essential role in drug development.. Some therapies have been developed and supervised

Accumulation of drug at the target tissue to targeted drug delivery.proposed drug coated nanoparticles and release of drug into the cells and mechanism of the

The swelling of the formulations of hydrochlorothiazide using polymers (carbopol 934p, HPMC K15M, HPMC K4M, PVP K30) were determined by water uptake of the tablet and

Therefore, when drug interacts with cyclodextrin molecule, drug will be entrapped inside cyclodexrin cavity to form a stable inclusion complex, thereby improving